Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472190 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| Piperazine SCHEMBL28199664 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL29832951 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL5550813 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL29604422 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL337070 | 0.98 | HSD17B10 (0.52) | CHRM5CHRM3HSD17B10SIGMAR1CA2 | |
| SCHEMBL62990 | 0.98 | HSD17B10 (0.52) | CHRM5CHRM3HSD17B10SIGMAR1CA2 | |
| SCHEMBL5556374 | 0.96 | CHRM5 (0.47) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| Hydrochloric Acid SCHEMBL1373260 | 0.95 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CA2 | |
| SCHEMBL472213 | 0.95 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | claimed |
| EP-4556029-A2 | RADIOPHARMACEUTICAL CONJUGATE | The South African Nuclear Energy Corporation Limited (ZA) | 2025-05-21 | — | — | EP | claimed |
| CN-119855612-A | Radionuclide coupling medicine, pharmaceutical composition and application thereof | 同宜医药（苏州）有限公司 | 2025-04-18 | — | — | CN | claimed |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2025-03-27 | — | — | US | claimed |
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-01-23 | — | — | US | claimed |
| EP-4479040-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-12-25 | — | — | EP | claimed |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2024-11-21 | — | — | US | claimed |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-11-19 | — | — | US | claimed |
| EP-4436979-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-10-02 | — | — | EP | claimed |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-08-29 | — | — | US | claimed |
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | claimed |
| EP-1602649-A2 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS | BRACCO S.p.A. (IT) | 2005-12-07 | — | — | EP | claimed |
| EP-0998476-B1 | 1,4,7,10-TETRAAZABICYCLO 8.2.2]TETRADECAN-2-ONE, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF FOR THE PREPARATION OF TETRAAZAMACROCYCLES | BRACCO SPA (IT) | 2004-05-06 | — | — | EP | claimed |
| US-6342597-B1 | CONDENSATION REACTION TRIETHYLENETETRAMINE WITH GLYOXAL TO CYCLIZE; OXIDATION, ALKYLATION, HYDROLYSIS, QUATERNIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING | DIBRA S.P.A. (IT) | 2002-01-29 | — | — | US | claimed |
| EP-0882010-B1 | PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-05-02 | — | — | EP | claimed |
| EP-1047677-A2 | Process for the preparation of derivatives of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid | BRACCO S.p.A. (IT) | 2000-11-02 | — | — | EP | claimed |
| EP-0998476-A1 | 1,4,7,10-TETRAAZABICYCLO 8.2.2]TETRADECAN-2-ONE, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF FOR THE PREPARATION OF TETRAAZAMACROCYCLES | BRACCO S.p.A. (IT) | 2000-05-10 | — | — | EP | claimed |
| US-6020485-A | Process for producing tetraazabicyclo monoacetic acid | DIBRA S.P.A. (IT) | 2000-02-01 | — | — | US | claimed |
| WO-1999035133-A2 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
| WO-1999005145-A1 | 1,4,7,10-TETRAAZABICYCLO[8.2.2]TETRADECAN-2-ONE, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF FOR THE PREPARATION OF TETRAAZAMACROCYCLES | BRACCO S.P.A. (IT) | 1999-02-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | CHRM5 683/4885CHRM3 346/4885HSD17B10 2840/4885 |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | CHRM5 1306/4885CHRM3 642/4885HSD17B10 2591/4885 |
| US-20240287046-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | CHRM5 717/4885CHRM3 368/4885HSD17B10 2630/4885 |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | CHRM5 1306/4885CHRM3 642/4885HSD17B10 2591/4885 |
| US-12145926-B2 | Compounds and radioligands for targeting neurotensin receptor and uses thereof | NTSR1, NTSR2, NPSR1 | CHRM5 717/4885CHRM3 368/4885HSD17B10 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.